306 related articles for article (PubMed ID: 23890009)
1. PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling.
Cai X; Xu Y; Cheung AK; Tomlinson RC; Alcázar-Román A; Murphy L; Billich A; Zhang B; Feng Y; Klumpp M; Rondeau JM; Fazal AN; Wilson CJ; Myer V; Joberty G; Bouwmeester T; Labow MA; Finan PM; Porter JA; Ploegh HL; Baird D; De Camilli P; Tallarico JA; Huang Q
Chem Biol; 2013 Jul; 20(7):912-21. PubMed ID: 23890009
[TBL] [Abstract][Full Text] [Related]
2. PIKfyve, a class III lipid kinase, is required for TLR-induced type I IFN production via modulation of ATF3.
Cai X; Xu Y; Kim YM; Loureiro J; Huang Q
J Immunol; 2014 Apr; 192(7):3383-9. PubMed ID: 24600036
[TBL] [Abstract][Full Text] [Related]
3. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency.
Billich A
IDrugs; 2007 Jan; 10(1):53-9. PubMed ID: 17187316
[TBL] [Abstract][Full Text] [Related]
4. Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation.
Sbrissa D; Naisan G; Ikonomov OC; Shisheva A
PLoS One; 2018; 13(9):e0204532. PubMed ID: 30240452
[TBL] [Abstract][Full Text] [Related]
5. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.
Nelson EA; Dyall J; Hoenen T; Barnes AB; Zhou H; Liang JY; Michelotti J; Dewey WH; DeWald LE; Bennett RS; Morris PJ; Guha R; Klumpp-Thomas C; McKnight C; Chen YC; Xu X; Wang A; Hughes E; Martin S; Thomas C; Jahrling PB; Hensley LE; Olinger GG; White JM
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005540. PubMed ID: 28403145
[TBL] [Abstract][Full Text] [Related]
6. The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.
Baranov MV; Bianchi F; van den Bogaart G
Cells; 2020 Dec; 10(1):. PubMed ID: 33375410
[TBL] [Abstract][Full Text] [Related]
7. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.
Krausz S; Boumans MJ; Gerlag DM; Lufkin J; van Kuijk AW; Bakker A; de Boer M; Lodde BM; Reedquist KA; Jacobson EW; O'Meara M; Tak PP
Arthritis Rheum; 2012 Jun; 64(6):1750-5. PubMed ID: 22170479
[TBL] [Abstract][Full Text] [Related]
8. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.
Gayle S; Landrette S; Beeharry N; Conrad C; Hernandez M; Beckett P; Ferguson SM; Mandelkern T; Zheng M; Xu T; Rothberg J; Lichenstein H
Blood; 2017 Mar; 129(13):1768-1778. PubMed ID: 28104689
[TBL] [Abstract][Full Text] [Related]
9. The Lipid Kinase PIKfyve Coordinates the Neutrophil Immune Response through the Activation of the Rac GTPase.
Dayam RM; Sun CX; Choy CH; Mancuso G; Glogauer M; Botelho RJ
J Immunol; 2017 Sep; 199(6):2096-2105. PubMed ID: 28779020
[TBL] [Abstract][Full Text] [Related]
10. Apilimod alters TGFβ signaling pathway and prevents cardiac fibrotic remodeling.
Cinato M; Guitou L; Saidi A; Timotin A; Sperazza E; Duparc T; Zolov SN; Giridharan SSP; Weisman LS; Martinez LO; Roncalli J; Kunduzova O; Tronchere H; Boal F
Theranostics; 2021; 11(13):6491-6506. PubMed ID: 33995670
[No Abstract] [Full Text] [Related]
11. PIKfyve inhibition increases exosome release and induces secretory autophagy.
Hessvik NP; Øverbye A; Brech A; Torgersen ML; Jakobsen IS; Sandvig K; Llorente A
Cell Mol Life Sci; 2016 Dec; 73(24):4717-4737. PubMed ID: 27438886
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.
Sands BE; Jacobson EW; Sylwestrowicz T; Younes Z; Dryden G; Fedorak R; Greenbloom S
Inflamm Bowel Dis; 2010 Jul; 16(7):1209-18. PubMed ID: 19918967
[TBL] [Abstract][Full Text] [Related]
13. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.
Wada Y; Cardinale I; Khatcherian A; Chu J; Kantor AB; Gottlieb AB; Tatsuta N; Jacobson E; Barsoum J; Krueger JG
PLoS One; 2012; 7(4):e35069. PubMed ID: 22493730
[TBL] [Abstract][Full Text] [Related]
14. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor.
Wada Y; Lu R; Zhou D; Chu J; Przewloka T; Zhang S; Li L; Wu Y; Qin J; Balasubramanyam V; Barsoum J; Ono M
Blood; 2007 Feb; 109(3):1156-64. PubMed ID: 17053051
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201.
Hayakawa N; Noguchi M; Takeshita S; Eviryanti A; Seki Y; Nishio H; Yokoyama R; Noguchi M; Shuto M; Shima Y; Kuribayashi K; Kageyama S; Eda H; Suzuki M; Hatta T; Iemura S; Natsume T; Tanabe I; Nakagawa R; Shiozaki M; Sakurai K; Shoji M; Andou A; Yamamoto T
Bioorg Med Chem; 2014 Jun; 22(11):3021-9. PubMed ID: 24767819
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2.
Kang YL; Chou YY; Rothlauf PW; Liu Z; Soh TK; Cureton D; Case JB; Chen RE; Diamond MS; Whelan SPJ; Kirchhausen T
Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20803-20813. PubMed ID: 32764148
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of c-Rel DNA binding is critical for the anti-inflammatory effects of novel PIKfyve inhibitor.
Terajima M; Kaneko-Kobayashi Y; Nakamura N; Yuri M; Hiramoto M; Naitou M; Hattori K; Yokota H; Mizuhara H; Higashi Y
Eur J Pharmacol; 2016 Jun; 780():93-105. PubMed ID: 27001378
[TBL] [Abstract][Full Text] [Related]
18. Snx10 and PIKfyve are required for lysosome formation in osteoclasts.
Sultana F; Morse LR; Picotto G; Liu W; Jha PK; Odgren PR; Battaglino RA
J Cell Biochem; 2020 Apr; 121(4):2927-2937. PubMed ID: 31692073
[TBL] [Abstract][Full Text] [Related]
19. The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells.
Wang H; Brown J; Gao S; Liang S; Jotwani R; Zhou H; Suttles J; Scott DA; Lamont RJ
J Immunol; 2013 Aug; 191(3):1164-74. PubMed ID: 23797672
[TBL] [Abstract][Full Text] [Related]
20. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.
Burakoff R; Barish CF; Riff D; Pruitt R; Chey WY; Farraye FA; Shafran I; Katz S; Krone CL; Vander Vliet M; Stevens C; Sherman ML; Jacobson E; Bleday R
Inflamm Bowel Dis; 2006 Jul; 12(7):558-65. PubMed ID: 16804392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]